Skip to Content
SEATTLE, WA – U.S. Representative Pramila Jayapal (WA-07) released the following statement following the Department of Justice’s (DOJ) filing of proposed remedies, including a potential breakup of the company to address their monopolistic practices:
“I applaud the Biden-Harris Administration and…
Issues:
Science, Technology, & Antitrust
SEATTLE – U.S. Representative Pramila Jayapal (WA-07) is today announcing her Community Project Funding (CPF) requests that she will be advocating to include in the Fiscal Year 2025 (FY25) appropriations bills. These 15 projects could bring up to $56 million…
Issues:
Arts & Education,
Environment,
Housing, Transportation, & Infrastructure,
Jobs, Labor, & the Economy,
Science, Technology, & Antitrust
WASHINGTON – U.S. Representative Pramila Jayapal (WA-07) released the following statement regarding her vote against H.R. 7521, the Protecting Americans from Foreign Adversary Controlled Applications Act. The legislation today passed the House by a vote of 352-65.
“I voted no…
Issues:
Foreign Affairs & National Security,
Science, Technology, & Antitrust
Warren, Jayapal Announce Three Drug Manufacturers Pulled Sham Patents after Warnings, Urge FDA to Continue Fight Against Big Pharma Companies’ Patent Abuse
Lawmakers Probed Big Pharma’s Sham Patent Claims after FTC Warnings in December 2023; Are Now Sharing Responses with…
Issues:
Health Care,
Science, Technology, & Antitrust
Members of CHIPS Investment Team Passed Through Revolving Door Between Government and Wall Street, Risking Misuse of Taxpayer Dollars
“Instead of building a broad-based team of experts from different sectors of government and the private sector, the Department has ‘been…
Issues:
Government Reform & Ethics,
Science, Technology, & Antitrust
WASHINGTON – U.S. Representatives Pramila Jayapal (WA-07), a member of the House Antitrust Subcommittee, and Jerrold Nadler (NY-12), Ranking Member of the Judiciary Committee, are today urging the Administration to consider judicial nominees’ records on antitrust and competition policy during…
Issues:
Science, Technology, & Antitrust
